Beyond the Annual Physical: what a longevity workup measures, and why it changes what you do next.

1The gap in the standard physical

If you have ever been told "your labs look normal" while feeling anything but, you have already met the limitation this paper is about.

The standard annual visit is built around a short list of screening tests and population reference ranges. A result is flagged when it falls outside the range that captures roughly ninety-five percent of the tested population. That is a sensible design for catching established disease at scale. It is a poor design for a person who wants to know whether their cardiovascular, metabolic and hormonal systems are on a good trajectory or a bad one, because "within range" and "optimal for you" are different questions.

Three things are usually missing. First, the panel is too narrow: a basic lipid panel does not include the markers that best predict atherosclerotic risk. Second, the interpretation is binary: normal or abnormal, with little attention to where in the range you sit or which direction you are moving. Third, there is no plan beyond "keep doing what you are doing" or a prescription. The visit ends with a verdict, not a trajectory.

Longevity medicine, done properly, is not an alternative to this visit. It is what comes after it: a deeper measurement, a physician who has time to read it, and a plan that is revised as the numbers move.

2The markers that matter

There is a long list of tests a person can buy. A shorter list has both a strong evidence base and a clear action attached to it. These are the ones we build a first assessment around.

Cardiovascular: ApoB and Lp(a)

Cardiovascular disease remains the leading cause of death in the United States, and most of it is atherosclerosis: the slow accumulation of cholesterol-carrying particles in artery walls. The number of those particles is measured directly by apolipoprotein B (ApoB). Standard LDL cholesterol estimates the cholesterol content of the particles, which is related but not the same, and the two can disagree in exactly the people who most need an accurate answer: those with metabolic syndrome, high triglycerides, or diabetes. Major cardiology consensus statements now describe ApoB as the more accurate measure of atherogenic burden. It is inexpensive and rarely ordered.

Lipoprotein(a), or Lp(a), is a second particle that raises cardiovascular risk independently. Its level is set largely by genetics, changes little with lifestyle, and is elevated in roughly one in five people. Most of them do not know it, because it is almost never part of a routine panel. Knowing your Lp(a) once changes how aggressively everything else should be managed.

Metabolic: insulin, glucose, and what sits between them

By the time fasting glucose or HbA1c crosses the threshold for prediabetes, insulin resistance has usually been present for years. Fasting insulin, the ratio-based estimates derived from it, and triglyceride-to-HDL relationships move earlier. Where a continuous glucose monitor is appropriate, two weeks of data shows how your body actually handles the meals you actually eat, which no single blood draw can.

Body composition, not weight

Weight tells you very little. A DEXA scan separates lean mass, fat mass and, importantly, visceral fat, the metabolically active fat around the organs. Low muscle mass and strength are associated with higher mortality across large cohorts, and muscle is lost steadily from midlife onward unless it is actively defended. A baseline scan turns "I should exercise more" into a specific target.

Cardiorespiratory fitness

Aerobic fitness, measured as VO2 max, is one of the strongest predictors of all-cause mortality that medicine has, stronger than most of the risk factors that are routinely treated. Large cohort studies have found no upper limit to the benefit. A measured VO2 max, or a well-run estimate, establishes where you are and how much room there is.

Hormones, read in context

Testosterone in men declines gradually through midlife; the perimenopausal transition in women changes estradiol, progesterone and the symptoms attached to them; thyroid function can be "normal" on TSH alone while free hormones tell a different story. A hormone panel is informative only when it is read against symptoms, sleep, body composition and the other markers above. That interpretation is the physician's job, and it is where a great deal of harm is done by a panel ordered without one.

Biological age, with a caveat

Epigenetic clocks estimate biological age from chemical marks on DNA. They are a promising research tool and a useful longitudinal baseline; they are not yet a clinical decision-maker. We use them the way we use a photograph: to see change over time, not to diagnose.

3From numbers to a plan

A result is only worth measuring if it changes what you do. Every marker above has a lever attached to it.

Most of the levers are not pharmaceutical. Resistance training defends muscle and improves insulin sensitivity. Zone 2 aerobic work and short high-intensity intervals raise VO2 max at any age. Protein intake set to body composition, not to a generic guideline, supports both. Sleep is where recovery, hormones and appetite regulation are decided, and it is the lever most people underestimate. A longevity plan is precise about these: how much, how often, measured against which number, re-tested when.

Medical therapy is added when the numbers make the case. Lipid-lowering therapy for an ApoB that lifestyle alone will not move to target. Metabolic medication when insulin resistance is established. Hormone optimization when a deficiency is measured, symptomatic, and the risks and benefits have been discussed with a physician who will monitor it.

A small number of patients are candidates for more advanced approaches. Therapeutic plasma exchange (TPE), which removes plasma along with the inflammatory and pro-aging factors circulating in it, is one of them. The evidence here is early: a randomized trial in Alzheimer's disease and a body of animal work on plasma dilution are why the field is paying attention, and why we offer it. We present it as what it is, an investigational approach for selected patients, discussed candidly, and never as a first step.

The test does not make anyone healthier. The plan does, and only if it is re-measured.

4What the first ninety days look like

1. Week one: the full baseline. Advanced blood work, body composition, fitness testing, and an hour with the physician on your history, your goals and what you have already tried.
2. Week two: the read-through. Every result explained, together, in plain language. Where you stand on each marker, which ones matter most for you, and the two or three that will drive the plan.
3. Weeks two to twelve: the plan in motion. Training, nutrition and sleep targets that are specific to your numbers. Medical therapy where it is indicated. Check-ins as the plan settles.
4. Week twelve: re-measure. The markers that were expected to move are tested again. The plan is adjusted on what changed, not on how it felt. This becomes the quarterly rhythm.

5Who this is for, and who it is not

This approach suits people who want to understand what is happening in their bodies and are willing to act on it: to train, to change how they eat and sleep, to take a medication when the case is made, and to come back and be measured again. It suits people who have felt dismissed by a system that only looks for disease already present.

It does not suit someone looking for a single test, a single supplement, or a single visit. It does not replace primary care, urgent care or specialist care for established disease, and we say so. And it is largely not covered by insurance, because insurance pays to treat disease, not to prevent it. That is an honest cost, and we are direct about it before anyone commits.

6Six questions to ask any longevity physician

1. Will you measure ApoB and Lp(a), and how will you act on the result?
2. How do you assess muscle mass and fitness, and what target will you set for me?
3. Who reads my results, and how long will we spend on them together?
4. What will you re-measure at ninety days, and what would make you change the plan?
5. When do you recommend medication, and when do you not?
6. For any advanced therapy you offer: what is the evidence, and how do you describe its limits?

Any physician worth trusting with your next twenty years should welcome all six.

This paper is educational and does not constitute medical advice. It does not establish a physician-patient relationship. Decisions about testing and treatment should be made with a licensed physician who knows your history.